Cheah Stefanie, Dee Simon, Cole Alexandra, Matzke Lise, O'Donoghue Sheila, Watson Peter H
1 BC BioLibrary, British Columbia, Canada .
Biopreserv Biobank. 2012 Dec;10(6):501-10. doi: 10.1089/bio.2012.0033.
Detailed documentation of the experimental materials and methods is essential for the validation of scientific papers. Human biospecimens are increasingly utilized as materials in cancer research and information about the biospecimens used is a component of this documentation. We hypothesized that previously reported biospecimen data are inadequate for accurate replication and/or validation of a substantial proportion of studies. To examine this issue, we analyzed biospecimen reporting in a representative cross section of publications over the past 12 years (1998, 2004, 2010) in the journals, Cancer Research (CR, n=46) and Clinical Cancer Research (CCR, n=73). We assessed biospecimen data in relation to the standards outlined as the Tier 1 recommended data elements from the Biospecimen Reporting for Improved Study Quality (BRISQ), in addition to ethics criteria. These data elements encompass features of biospecimens influenced by the patient, medical procedure, and biospecimen acquisition, handling and storage processes. Analysis found that while there was a significant increase in the reporting of ethics board approval status (p<0.008) and name of the ethics board (p<0.0001), there were no significant differences between these journals or over this period in reporting other biospecimen-related data elements. Of the 15 Tier 1 data elements assessed in CR and CCR, the data elements commonly obtained from the "Clinical Chart" (8/15 elements) were significantly better reported than elements that would typically be obtained from the "Biobank" (p<0.0001). Our findings demonstrate that reporting of biospecimen-related data elements has been incomplete. As one part of the solution to this issue, we propose the use of an online data-elements reporting tool (www.biobanking.ca) by biobanks. This BRISQ Report tool aims to help biobanks provide the relevant biospecimen-related data as a structured report, and to promote its inclusion as supplementary material in publications to improve the quality of future research studies.
详细记录实验材料和方法对于科学论文的验证至关重要。人体生物标本在癌症研究中越来越多地被用作材料，所使用生物标本的信息是该记录的一个组成部分。我们假设，先前报告的生物标本数据不足以准确复制和/或验证相当一部分研究。为了研究这个问题，我们分析了过去12年（1998年、2004年、2010年）发表在《癌症研究》（CR，n = 46）和《临床癌症研究》（CCR，n = 73）杂志上的代表性出版物样本中的生物标本报告情况。除了伦理标准外，我们还根据《提高研究质量生物标本报告》（BRISQ）中列为一级推荐数据元素的标准评估了生物标本数据。这些数据元素包括受患者、医疗程序以及生物标本采集、处理和存储过程影响的生物标本特征。分析发现，虽然伦理委员会批准状态（p < 0.008）和伦理委员会名称（p < 0.0001）的报告有显著增加，但在报告其他生物标本相关数据元素方面，这些杂志之间或在此期间没有显著差异。在CR和CCR评估的15个一级数据元素中，通常从“临床图表”获得的数据元素（8/15个元素）的报告明显优于通常从“生物样本库”获得的元素（p < 0.0001）。我们的研究结果表明，生物标本相关数据元素的报告并不完整。作为解决这个问题的一部分，我们建议生物样本库使用在线数据元素报告工具（www.biobanking.ca）。这个BRISQ报告工具旨在帮助生物样本库以结构化报告的形式提供相关的生物标本相关数据，并促进其作为补充材料纳入出版物，以提高未来研究的质量。
